Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Extension Study of KVD900 for On-demand Treatment of Hereditary Angioedema Attacks
jRCT2061230005Completed
- Sponsor
- KalVista Pharmaceuticals
- Start
- Aug 2023
- Modality
- Small Molecules
01
Overview
Open-label trial of sebetralstat in hereditary angioedema type I (HAE-I) and Hereditary Angioedema Type 2 (HAE2) (2 arms), sponsored by KalVista Pharmaceuticals. Started Aug 2023; status: completed.
02
Drugs
sebetralstat
03
Conditions
hereditary angioedema type I (HAE-I)Hereditary Angioedema Type 2 (HAE2)
Beyond the preview
Go deeper on jRCT2061230005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230005.